Free shipping on all orders over $ 500

CNX-774

Cat. No. M2536
CNX-774 Structure
Size Price Availability Quantity
10mg USD 200  USD200 In stock
50mg USD 660  USD660 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

Chemical Information
Molecular Weight 499.5
Formula C26H22FN7O3
CAS Number 1202759-32-7
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Jeong-Mi Kim, et al. Bruton's agammaglobulinemia tyrosine kinase (Btk) regulates TPA‑induced breast cancer cell invasion via PLCγ2/PKCβ/NF‑κB/AP‑1‑dependent matrix metalloproteinase‑9 activation

[2] D Smiljkovic, et al. BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils

[3] Akintunde Akinleye, et al. Ibrutinib and novel BTK inhibitors in clinical development

Related BTK Products
BCPyr

BCPyr is a new candidate BTK degradation agent (DC50 = 800 nM).

BMS-986143

BMS-986143 is a potent, reversible inhibitor of tyrosine kinase (BTK), which has been successfully targeted by a number of irreversible tumor compounds.

BIIB091

The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis.

TAK-020

TAK-020 is a highly selective oral covalent BTK inhibitor with a promising safety and tolerability profile for both hematologic malignancies and autoimmune diseases.

BTK inhibitor 1 (Compound 27)

BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: CNX-774 supplier, BTK, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.